Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
about
Pharmacology and rationale for imatinib in the treatment of sclerodermaImatinib: a breakthrough of targeted therapy in cancer.Atopic Dermatitis-like Graft-versus-host Disease and Lichen Planus-like Graft-versus-host Disease: Alterations in Skin Barrier Function and Related Molecules.Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation.Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease.
P2860
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
@en
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
@nl
type
label
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
@en
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
@nl
prefLabel
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
@en
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
@nl
P2093
P2860
P921
P356
P1476
Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.
@en
P2093
Attilio Olivieri
Imma Attolico
Jacopo Olivieri
Sabrina Coluzzi
P2860
P304
P356
10.1100/2011/924954
P407
P577
2011-10-25T00:00:00Z